AEON Bio - AEON Net earnings per share growth forecast for next year

Corporate company logo of AEON Biopharma, Inc. (AEON)

Cold chain supply optimization for neurological agents ensures stable margins for AEON Biopharma (AEON). The consensus EPS forecast for the coming year confirms this efficiency, with 33.50 becoming the new value for this metric. The business relies on external manufacturing and marketing partners, while expanding the compliance expert staff while maintaining the core R&D team guarantees the quality of future developments.

AEON Bio (AEON): Net earnings per share growth forecast for next year from 02/21/2024 to 11/14/2026

Summary analytical data breakdowns for AEON Biopharma, Inc. (AEON)

- price and consensus price forecast:
Price Chart AEON Biopharma Inc.|AEON - Fair Value Consensus
- issuer market value details:
Market Value AEON Biopharma|AEON - Total Enterprise Value
- company book value details:
Net Assets per Single Share AEON Biopharma|AEON - Company Book Value|Market Value to Book Value Ratio aeonbiopharma.com|AEON - Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital AEON Biopharma|AEON - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio AEON Biopharma Inc.|AEON - Company Cumulative Debt|Debts to Book Capitalization AEON Biopharma|AEON - Company Long-Term Debts|Company Short-Term Debts AEON Biopharma|Quick Liquidity aeonbiopharma.com
- net income and valuation ratios data:
AEON - Company Net Income|Expected Profit AEON Biopharma|AEON - Price to Earnings Multiple|Projected Price to Earnings AEON Biopharma Inc.|AEON - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple AEON Biopharma|AEON - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) AEON Biopharma|AEON - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months aeonbiopharma.com|AEON - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year AEON Biopharma
- company sales and revenue statistics:
AEON - Company Annual Revenue|Projected Sales Volume AEON Biopharma Inc.|AEON - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple AEON Biopharma
Fundamental company analysis:AEON Biopharma, AEON
Finished products of AEON Bio

AEON Biopharma is currently in the clinical trial stage with no current revenue, meaning its valuation is based exclusively on future patents. The historical trend of next year's EPS forecast reflects consolidated analyst expectations for profit growth rates, allowing investors to assess the probability of commercial success for its drugs and avoid overpaying for the asset at the peak of optimism.

Main competitors

Net earnings per share growth forecast for next year Jazz Pharma|CYTK: Expected earnings per share trend next year|Net earnings per share growth forecast for next year PTC Therapeutics, Inc. (PTCT)|SRRK - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Centessa CNTA|Dyne Therapeutics Inc - Net earnings per share growth forecast for next year|EWTX - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Rapport Corp|ALMS: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year zevra.com ZVRA|Expected earnings per share growth for next year CTNM|Expected net earnings per share growth next year Larimar Therapeutics Inc LRMR|Earnings growth forecast for next year CAPR|Earnings growth forecast for next year Entrada Therapeutics, Inc (TRDA)|Earnings growth forecast for next year PTHS (Channel Therapeutics)|MediciNova Inc. (MNOV) - Expected net earnings per share growth next year|SER - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year BioXcel Therapeutics Inc|promisneurosciences.com (PMN) - Net earnings per share growth forecast for next year|Projected earnings per share growth rate for next year APUS|Expected earnings per share growth for next year NLSP|BNOX: Expected earnings per share trend next year|Earnings growth forecast for next year HUGE|Net earnings per share growth forecast for next year RETA (Reata Pharmaceuticals Inc)